My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: No — compounded GLP‑1s are usually not the best first option. They carry safety, quality and legal/coverage risks. There are safer, better‑documented routes to try first.

Why not compounded GLP‑1s

• They are not FDA‑approved products: potency, sterility and purity can vary. The FDA has warned about compounded versions of popular GLP‑1s.
• No standard labeling, batch testing or recall protections like an FDA product has.
• Most insurers will not cover compounded versions, so you pay out‑of‑pocket for something riskier.
• Potential contamination or incorrect dosing has real safety implications for injectables.

Safer alternatives and practical next steps

1. Appeal the insurance denial

   • Get the denial reason in writing. Ask your prescriber to submit or re-submit a prior authorization (PA) with a letter of medical necessity, your BMI, comorbidities (HTN, diabetes, OSA, etc.), and documentation of prior weight‑loss attempts.
   • Request a peer‑to‑peer review between your prescriber and the insurer’s medical reviewer.
   • Ask about an exception or step‑therapy override if the insurer requires trying other treatments first.

2. Check manufacturer support and savings programs

   • Novo Nordisk (Wegovy/Ozempic) has patient support and copay/savings options (search Wegovy Savings/ NovoCare). These often help commercially insured patients or offer PAPs for eligible uninsured/low‑income patients.
   • Eli Lilly (Mounjaro for diabetes, Zepbound for weight management) has patient support and savings programs as well.
   • Use discount services (GoodRx, SingleCare) to compare prices if you must pay out of pocket.

3. Consider covered, FDA‑approved alternatives

   • Ozempic (semaglutide) — approved for type 2 diabetes and sometimes covered (physician can discuss off‑label weight uses).
   • Zepbound (tirzepatide) and Mounjaro (tirzepatide for diabetes) — tirzepatide is approved for weight management (Zepbound) or diabetes (Mounjaro); coverage depends on plan.
   • Saxenda (liraglutide) — FDA‑approved for weight management.
   • Non‑GLP‑1 weight medications: Qsymia (phentermine/topiramate), Contrave (bupropion/naltrexone) — may be covered and could be options depending on your medical profile. Talk with your clinician about which alternative fits your medical history and which are most likely to be authorized.

4. Try clinical trials, telemedicine hubs, or specialist clinics

   • Weight‑management clinics and academic centers sometimes have programs or trials that provide access to GLP‑1s at lower cost or through research enrollment.
   • Your clinician or a local academic medical center can help find trials.

If you still consider compounded GLP‑1s (last‑resort, informed decision)

• Only use a PCAB‑accredited compounding pharmacy and ask to see sterility testing and a certificate of analysis (COA) for the batch.
• Ask exactly where the active pharmaceutical ingredient (API) came from, what testing was done, and request written documentation of lot testing and expiration dating.
• Understand your insurer likely will not cover the cost, and get written informed consent recognizing the risks.
• Consider discussing risks with an endocrinologist before proceeding.

Who to contact next

• Your prescriber (for PA/appeal and alternatives).
• Novo Nordisk and Eli Lilly patient support lines for savings programs and assistance.
• Your insurer’s member services for the appeals process and criteria.
• A PCAB‑accredited compounding pharmacy only if you decide to pursue compounding.

If you want, tell me:

• the denial reason (if you have it),
• whether you have diabetes or other obesity‑related conditions,
• and whether you’re willing to try other approved meds — and I’ll draft a sample appeal letter or suggest the best covered alternatives for your situation.